Affordable Access

deepdyve-link
Publisher Website

Are adipokines associated with atrial fibrillation in type 2 diabetes?

Authors
  • Peller, Michał1
  • Kapłon-Cieślicka, Agnieszka2
  • Rosiak, Marek3
  • Tymińska, Agata1
  • Ozierański, Krzysztof1
  • Eyileten, Ceren4
  • Kondracka, Agnieszka5
  • Mirowska-Guzel, Dagmara4
  • Opolski, Grzegorz1
  • Postuła, Marek4
  • Filipiak, Krzysztof J1
  • 1 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland. , (Poland)
  • 2 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland. [email protected] , (Poland)
  • 3 Department of Cardiology and Hypertension, Central Clinical Hospital, the Ministry of the Interior and Administration, Warsaw, Poland. , (Poland)
  • 4 Centre for Preclinical Research and Technology (CePT), Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland. , (Poland)
  • 5 Department of Internal Diseases and Endocrinology, Medical University of Warsaw, Warsaw, Poland. , (Poland)
Type
Published Article
Journal
Endokrynologia Polska
Publication Date
Jan 01, 2020
Volume
71
Issue
1
Pages
34–41
Identifiers
DOI: 10.5603/EP.a2019.0059
PMID: 33140400
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The potential effect of adipokines on the development of AF is yet to be established. The aim of this study was to investigate the association of baseline serum adipokines with 1) the presence of AF at baseline and 2) future risk of AF development. The current study is a sub-analysis of the prospective, randomised AVOCADO (Aspirin Vs./Or Clopidogrel in Aspirin-resistant Diabetics inflammation Outcomes) trial. The AVOCADO study included patients with type 2 DM burdened with at least two additional cardiovascular risk factors and receiving acetylsalicylic acid. In patients included in the current analysis adipokines and inflammatory biomarker levels were measured. Information on the subsequent AF diagnosis was collected after a median of 5.4 years of follow-up. A total of 273 patients with type 2 DM (median age 68 years; 52% male) were included in the initial analysis comparing patients with and without AF at baseline. Patients with diagnosed AF (12%) had higher levels of serum resistin [8.5 (5.8-10.5) vs. 6.9 (5.6-8.7) ng/mL; p = 0.034], adiponectin [6.9 (5.6-8.7) vs. 2.7 (1.8-4.2) ng/mL; p = 0.032], and N-terminal pro-B-type natriuretic peptide [336 (148-473) vs. 108 [45-217]; p < 0.001) than non-AF patients. There were no significant differences in serum leptin, IL-6, and TNF-alpha concentrations between the two groups. From subjects without known AF at study entry, 19% developed AF at follow-up. In logistic regression analysis, baseline adipokine levels did not predict AF development. In type 2 DM, patients with AF have higher resistin and adiponectin concentrations than patients with no AF. None of the studied adipokines proved a predictor of future AF development.

Report this publication

Statistics

Seen <100 times